1767 related articles for article (PubMed ID: 12355489)
1. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
2. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
3. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
4. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
Khanna D; Furst DE; Clements PJ; Park GS; Hays RD; Yoon J; Korn JH; Merkel PA; Rothfield N; Wigley FM; Moreland LW; Silver R; Steen VD; Weisman M; Mayes MD; Collier DH; Medsger TA; Seibold JR; ;
J Rheumatol; 2005 May; 32(5):832-40. PubMed ID: 15868618
[TBL] [Abstract][Full Text] [Related]
5. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
[TBL] [Abstract][Full Text] [Related]
6. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey.
Rannou F; Poiraudeau S; Berezné A; Baubet T; Le-Guern V; Cabane J; Guillevin L; Revel M; Fermanian J; Mouthon L
Arthritis Rheum; 2007 Feb; 57(1):94-102. PubMed ID: 17266096
[TBL] [Abstract][Full Text] [Related]
7. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.
Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin R; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold J
Arthritis Rheum; 1999 Nov; 42(11):2372-80. PubMed ID: 10555033
[TBL] [Abstract][Full Text] [Related]
8. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Seibold JR
Arthritis Rheum; 2001 Mar; 44(3):653-61. PubMed ID: 11263780
[TBL] [Abstract][Full Text] [Related]
9. The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma.
Sekhon S; Pope J; ; Baron M
J Rheumatol; 2010 Mar; 37(3):591-8. PubMed ID: 20080913
[TBL] [Abstract][Full Text] [Related]
10. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification.
Blackmore MG; Gladman DD; Husted J; Long JA; Farewell VT
J Rheumatol; 1995 May; 22(5):886-93. PubMed ID: 8587077
[TBL] [Abstract][Full Text] [Related]
11. Using a self-reported functional score to assess disease progression in systemic sclerosis.
Serednicka K; Smyth AE; Black CM; Denton CP
Rheumatology (Oxford); 2007 Jul; 46(7):1107-10. PubMed ID: 17426141
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
13. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
[TBL] [Abstract][Full Text] [Related]
14. A cross-sectional comparison of three self-reported functional indices in scleroderma.
Smyth AE; MacGregor AJ; Mukerjee D; Brough GM; Black CM; Denton CP
Rheumatology (Oxford); 2003 Jun; 42(6):732-8. PubMed ID: 12730528
[TBL] [Abstract][Full Text] [Related]
15. The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials.
Pope JE; Khanna D; Norrie D; Ouimet JM
J Rheumatol; 2009 Feb; 36(2):254-9. PubMed ID: 19132791
[TBL] [Abstract][Full Text] [Related]
16. Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials.
Pope JE; Bellamy N
Clin Invest Med; 1995 Feb; 18(1):1-10. PubMed ID: 7768060
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity to change of AIMS2 and AIMS2-SF components in comparison to M-HAQ and VAS-pain.
Taal E; Rasker JJ; Riemsma RP
Ann Rheum Dis; 2004 Dec; 63(12):1655-8. PubMed ID: 15547091
[TBL] [Abstract][Full Text] [Related]
18. Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis.
Watson HR; Robb R; Belcher G; Belch JJ
J Rheumatol; 1999 Aug; 26(8):1734-7. PubMed ID: 10451070
[TBL] [Abstract][Full Text] [Related]
19. Ulnar artery involvement in systemic sclerosis (scleroderma).
Taylor MH; McFadden JA; Bolster MB; Silver RM
J Rheumatol; 2002 Jan; 29(1):102-6. PubMed ID: 11824945
[TBL] [Abstract][Full Text] [Related]
20. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.
Sambo P; Amico D; Giacomelli R; Matucci-Cerinic M; Salsano F; Valentini G; Gabrielli A
J Rheumatol; 2001 Oct; 28(10):2257-62. PubMed ID: 11669166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
